Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Hereditary Cancer Evaluation in 2019-a Rapidly Evolving Landscape.

Yung RL, Korde LA.

JAMA Oncol. 2019 Aug 20. doi: 10.1001/jamaoncol.2019.3431. [Epub ahead of print] No abstract available.

PMID:
31429864
2.

Are we assuming too much with our statistical assumptions? Lessons learned from the ALTTO trial.

Holmes EM, Bradbury I, Williams LS, Korde L, de Azambuja E, Fumagalli D, Moreno-Aspitia A, Baselga J, Piccart-Gebhart M, Dueck AC, Gelber RD; ALTTO Trial Study Team.

Ann Oncol. 2019 Sep 1;30(9):1507-1513. doi: 10.1093/annonc/mdz195.

PMID:
31240310
3.

Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial.

Lambertini M, Campbell C, Gelber RD, Viale G, McCullough A, Hilbers F, Korde LA, Werner O, Chumsri S, Jackisch C, Wolff AC, Vaz-Luis I, Ferreira AR, Prat A, Moreno-Aspitia A, Piccart M, Loi S, de Azambuja E.

Breast Cancer Res Treat. 2019 Aug;177(1):103-114. doi: 10.1007/s10549-019-05284-y. Epub 2019 May 27.

PMID:
31134488
4.

Oncologists' Attitudes and Practice of Addressing Diet, Physical Activity, and Weight Management With Patients With Cancer: Findings of an ASCO Survey of the Oncology Workforce.

Ligibel JA, Jones LW, Brewster AM, Clinton SK, Korde LA, Oeffinger KC, Bender CM, Tan W, Merrill JK, Katta S, Alfano CM.

J Oncol Pract. 2019 Jun;15(6):e520-e528. doi: 10.1200/JOP.19.00124. Epub 2019 May 16.

5.

Current Landscape of Immunotherapy in Breast Cancer: A Review.

Adams S, Gatti-Mays ME, Kalinsky K, Korde LA, Sharon E, Amiri-Kordestani L, Bear H, McArthur HL, Frank E, Perlmutter J, Page DB, Vincent B, Hayes JF, Gulley JL, Litton JK, Hortobagyi GN, Chia S, Krop I, White J, Sparano J, Disis ML, Mittendorf EA.

JAMA Oncol. 2019 Apr 11. doi: 10.1001/jamaoncol.2018.7147. [Epub ahead of print]

PMID:
30973611
6.

Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer-A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib.

Symonds L, Linden H, Gadi V, Korde L, Rodler E, Gralow J, Redman M, Baker K, Wu QV, Jenkins I, Kurland B, Garrison M, Smith J, Anderson J, Van Haelst C; Seattle Cancer Care Alliance Network Investigators, Specht J.

Clin Breast Cancer. 2019 Apr;19(2):e283-e296. doi: 10.1016/j.clbc.2018.12.008. Epub 2018 Dec 14.

PMID:
30737173
7.

Sex Hormones in Women With Elevated Breast Cancer Risk Undergoing Weight Loss.

Stone SA, Han CJ, Senn T, Korde LA, Allott K, Reding S, Whittington D, Reding KW.

West J Nurs Res. 2019 Nov;41(11):1602-1622. doi: 10.1177/0193945918820672. Epub 2019 Jan 7.

PMID:
30616442
8.

Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials.

Lambertini M, Martel S, Campbell C, Guillaume S, Hilbers FS, Schuehly U, Korde L, Azim HA Jr, Di Cosimo S, Tenglin RC, Huober J, Baselga J, Moreno-Aspitia A, Piccart-Gebhart M, Gelber RD, de Azambuja E, Ignatiadis M.

Cancer. 2019 Jan 15;125(2):307-316. doi: 10.1002/cncr.31784. Epub 2018 Oct 18.

9.

National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast Cancer.

Seidman AD, Bordeleau L, Fehrenbacher L, Barlow WE, Perlmutter J, Rubinstein L, Wedam SB, Hershman DL, Hayes JF, Butler LP, Smith ML, Regan MM, Beaver JA, Amiri-Kordestani L, Rastogi P, Zujewski JA, Korde LA.

J Clin Oncol. 2018 Sep 13:JCO1800242. doi: 10.1200/JCO.18.00242. [Epub ahead of print]

PMID:
30212295
10.

Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients.

Lambertini M, Campbell C, Bines J, Korde LA, Izquierdo M, Fumagalli D, Del Mastro L, Ignatiadis M, Pritchard K, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Barrios CH, Baselga J, Moreno-Aspitia A, Piccart M, Gelber RD, de Azambuja E.

J Natl Cancer Inst. 2019 Jan 1;111(1):86-94. doi: 10.1093/jnci/djy094. Erratum in: J Natl Cancer Inst. 2019 Nov 1;111(11):1237.

11.

Bisphosphonate Use and Risk of Recurrence, Second Primary Breast Cancer, and Breast Cancer Mortality in a Population-Based Cohort of Breast Cancer Patients.

Korde LA, Doody DR, Hsu L, Porter PL, Malone KE.

Cancer Epidemiol Biomarkers Prev. 2018 Feb;27(2):165-173. doi: 10.1158/1055-9965.EPI-17-0556. Epub 2017 Dec 18.

12.

Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.

Cardoso F, Bartlett JMS, Slaets L, van Deurzen CHM, van Leeuwen-Stok E, Porter P, Linderholm B, Hedenfalk I, Schröder C, Martens J, Bayani J, van Asperen C, Murray M, Hudis C, Middleton L, Vermeij J, Punie K, Fraser J, Nowaczyk M, Rubio IT, Aebi S, Kelly C, Ruddy KJ, Winer E, Nilsson C, Dal Lago L, Korde L, Benstead K, Bogler O, Goulioti T, Peric A, Litière S, Aalders KC, Poncet C, Tryfonidis K, Giordano SH.

Ann Oncol. 2018 Feb 1;29(2):405-417. doi: 10.1093/annonc/mdx651.

13.

Ductal Carcinoma in Situ: Quantitative Preoperative Breast MR Imaging Features Associated with Recurrence after Treatment.

Luo J, Johnston BS, Kitsch AE, Hippe DS, Korde LA, Javid S, Lee JM, Peacock S, Lehman CD, Partridge SC, Rahbar H.

Radiology. 2017 Dec;285(3):788-797. doi: 10.1148/radiol.2017170587. Epub 2017 Sep 14.

14.

Solitary Orbital Metastasis 35 Years after a Diagnosis of Lobular Carcinoma in Situ.

Spraker MB, Francis CE, Korde L, Kim J, Halasz L.

Cureus. 2017 Jun 28;9(6):e1404. doi: 10.7759/cureus.1404.

15.

Oncology Physicians' Perspectives on Practices and Barriers to Fertility Preservation and the Feasibility of a Prospective Study of Pregnancy After Breast Cancer.

Rosenberg SM, Gelber S, Gelber RD, Krop E, Korde LA, Pagani O, Partridge AH.

J Adolesc Young Adult Oncol. 2017 Sep;6(3):429-434. doi: 10.1089/jayao.2017.0031. Epub 2017 Jul 7.

16.

Gene expression in breast and adipose tissue after 12 months of weight loss and vitamin D supplementation in postmenopausal women.

Mason C, Wang L, Duggan C, Imayama I, Thomas SS, Wang CY, Korde LA, McTiernan A.

NPJ Breast Cancer. 2017 Apr 21;3:15. doi: 10.1038/s41523-017-0019-5. eCollection 2017.

17.

Investigation of a Lifestyle Intervention in Women at High Risk of Breast Cancer.

Han CJ, Korde LA, Reding S, Allott K, Van Doren M, Schwarz Y, Vaughan C, Reding KW.

West J Nurs Res. 2018 Jul;40(7):976-996. doi: 10.1177/0193945917697227. Epub 2017 Mar 23.

PMID:
28335697
18.

Repletion of vitamin D associated with deterioration of sleep quality among postmenopausal women.

Mason C, de Dieu Tapsoba J, Duggan C, Wang CY, Korde L, McTiernan A.

Prev Med. 2016 Dec;93:166-170. doi: 10.1016/j.ypmed.2016.09.035. Epub 2016 Sep 28.

19.

Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline.

Rugo HS, Rumble RB, Macrae E, Barton DL, Connolly HK, Dickler MN, Fallowfield L, Fowble B, Ingle JN, Jahanzeb M, Johnston SR, Korde LA, Khatcheressian JL, Mehta RS, Muss HB, Burstein HJ.

J Clin Oncol. 2016 Sep 1;34(25):3069-103. doi: 10.1200/JCO.2016.67.1487. Epub 2016 May 23.

PMID:
27217461
20.

Effects of Vitamin D3 Supplementation on Lean Mass, Muscle Strength, and Bone Mineral Density During Weight Loss: A Double-Blind Randomized Controlled Trial.

Mason C, Tapsoba JD, Duggan C, Imayama I, Wang CY, Korde L, McTiernan A.

J Am Geriatr Soc. 2016 Apr;64(4):769-78. doi: 10.1111/jgs.14049. Epub 2016 Apr 5.

21.

Effects of vitamin D supplementation during weight loss on sex hormones in postmenopausal women.

Mason C, De Dieu Tapsoba J, Duggan C, Imayama I, Wang CY, Korde LA, Stanczyk F, McTiernan A.

Menopause. 2016 Jun;23(6):645-52. doi: 10.1097/GME.0000000000000600.

22.

Breast Cancer in Young Women: Research Priorities. A Report of the Young Survival Coalition Research Think Tank Meeting.

Korde LA, Partridge AH, Esser M, Lewis S, Simha J, Johnson RH.

J Adolesc Young Adult Oncol. 2015 Mar;4(1):34-43. doi: 10.1089/jayao.2014.0049.

PMID:
26812429
23.

Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer.

Rodler ET, Kurland BF, Griffin M, Gralow JR, Porter P, Yeh RF, Gadi VK, Guenthoer J, Beumer JH, Korde L, Strychor S, Kiesel BF, Linden HM, Thompson JA, Swisher E, Chai X, Shepherd S, Giranda V, Specht JM.

Clin Cancer Res. 2016 Jun 15;22(12):2855-64. doi: 10.1158/1078-0432.CCR-15-2137. Epub 2016 Jan 22.

24.

Exemestane Use in Postmenopausal Women at High Risk for Invasive Breast Cancer: Evaluating Biomarkers of Efficacy and Safety.

Gatti-Mays ME, Venzon D, Galbo CE, Singer A, Reynolds J, Makariou E, Kallakury B, Heckman-Stoddard BM, Korde L, Isaacs C, Warren R, Gallagher A, Eng-Wong J.

Cancer Prev Res (Phila). 2016 Mar;9(3):225-33. doi: 10.1158/1940-6207.CAPR-15-0269. Epub 2016 Jan 12.

25.

Breast Cancer Risk Reduction, Version 2.2015.

Bevers TB, Ward JH, Arun BK, Colditz GA, Cowan KH, Daly MB, Garber JE, Gemignani ML, Gradishar WJ, Jordan JA, Korde LA, Kounalakis N, Krontiras H, Kumar S, Kurian A, Laronga C, Layman RM, Loftus LS, Mahoney MC, Merajver SD, Meszoely IM, Mortimer J, Newman L, Pritchard E, Pruthi S, Seewaldt V, Specht MC, Visvanathan K, Wallace A, Bergman MA, Kumar R.

J Natl Compr Canc Netw. 2015 Jul;13(7):880-915.

PMID:
26150582
26.

Male Breast Cancer: A Study in Small Steps.

Korde LA.

Oncologist. 2015 Jun;20(6):584-5. doi: 10.1634/theoncologist.2015-0174. Epub 2015 May 18. No abstract available.

27.

Are Qualitative Assessments of Background Parenchymal Enhancement, Amount of Fibroglandular Tissue on MR Images, and Mammographic Density Associated with Breast Cancer Risk?

Dontchos BN, Rahbar H, Partridge SC, Korde LA, Lam DL, Scheel JR, Peacock S, Lehman CD.

Radiology. 2015 Aug;276(2):371-80. doi: 10.1148/radiol.2015142304. Epub 2015 May 12.

28.

Effect of Vitamin D3 Supplementation in Combination with Weight Loss on Inflammatory Biomarkers in Postmenopausal Women: A Randomized Controlled Trial.

Duggan C, de Dieu Tapsoba J, Mason C, Imayama I, Korde L, Wang CY, McTiernan A.

Cancer Prev Res (Phila). 2015 Jul;8(7):628-35. doi: 10.1158/1940-6207.CAPR-14-0449. Epub 2015 Apr 23.

29.

The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer.

DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ.

Clin Cancer Res. 2015 Jul 1;21(13):2911-5. doi: 10.1158/1078-0432.CCR-14-1760. Epub 2015 Feb 24.

30.

Pregnancy after breast cancer: Are young patients willing to participate in clinical studies?

Pagani O, Ruggeri M, Manunta S, Saunders C, Peccatori F, Cardoso F, Kaufman B, Paluch-Shimon S, Gewefel H, Gallerani E, Abulkhair OM, Pistilli B, Warner E, Saloustros E, Perey L, Zaman K, Rabaglio M, Gelber S, Gelber RD, Goldhirsch A, Korde L, Azim HA Jr, Partridge AH.

Breast. 2015 Jun;24(3):201-7. doi: 10.1016/j.breast.2015.01.005. Epub 2015 Feb 4.

PMID:
25662412
31.

Genetics of breast cancer: a topic in evolution.

Shiovitz S, Korde LA.

Ann Oncol. 2015 Jul;26(7):1291-9. doi: 10.1093/annonc/mdv022. Epub 2015 Jan 20. Review.

32.

Renaming ductal carcinoma in situ: would removing "carcinoma" reduce overtreatment?

Javid SH, Fang LC, Korde L, Anderson BO.

J Natl Compr Canc Netw. 2014 Apr;12(4):599-602. No abstract available.

PMID:
24717574
33.

Vitamin D3 supplementation during weight loss: a double-blind randomized controlled trial.

Mason C, Xiao L, Imayama I, Duggan C, Wang CY, Korde L, McTiernan A.

Am J Clin Nutr. 2014 May;99(5):1015-25. doi: 10.3945/ajcn.113.073734. Epub 2014 Mar 12. Erratum in: Am J Clin Nutr. 2014 Oct;100(4):1213.

34.

Predictors and outcomes of completion axillary node dissection among older breast cancer patients.

Javid SH, He H, Korde LA, Flum DR, Anderson BO.

Ann Surg Oncol. 2014 Jul;21(7):2172-80. doi: 10.1245/s10434-014-3595-8. Epub 2014 Mar 1.

35.

Familial testicular germ cell tumor: no associated syndromic pattern identified.

Mueller CM, Korde LA, McMaster ML, Peters JA, Bratslavsky G, Watkins RJ, Ling A, Kratz CP, Wulfsberg EA, Rosenberg PS, Greene MH.

Hered Cancer Clin Pract. 2014 Feb 21;12(1):3. doi: 10.1186/1897-4287-12-3.

36.

Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement.

Meyerhardt JA, Mangu PB, Flynn PJ, Korde L, Loprinzi CL, Minsky BD, Petrelli NJ, Ryan K, Schrag DH, Wong SL, Benson AB 3rd; American Society of Clinical Oncology.

J Clin Oncol. 2013 Dec 10;31(35):4465-70. doi: 10.1200/JCO.2013.50.7442. Epub 2013 Nov 12.

PMID:
24220554
37.

Meta-analysis identifies four new loci associated with testicular germ cell tumor.

Chung CC, Kanetsky PA, Wang Z, Hildebrandt MA, Koster R, Skotheim RI, Kratz CP, Turnbull C, Cortessis VK, Bakken AC, Bishop DT, Cook MB, Erickson RL, Fosså SD, Jacobs KB, Korde LA, Kraggerud SM, Lothe RA, Loud JT, Rahman N, Skinner EC, Thomas DC, Wu X, Yeager M, Schumacher FR, Greene MH, Schwartz SM, McGlynn KA, Chanock SJ, Nathanson KL.

Nat Genet. 2013 Jun;45(6):680-5. doi: 10.1038/ng.2634. Epub 2013 May 12.

38.

Testicular germ cell tumor susceptibility associated with the UCK2 locus on chromosome 1q23.

Schumacher FR, Wang Z, Skotheim RI, Koster R, Chung CC, Hildebrandt MA, Kratz CP, Bakken AC, Bishop DT, Cook MB, Erickson RL, Fosså SD, Greene MH, Jacobs KB, Kanetsky PA, Kolonel LN, Loud JT, Korde LA, Le Marchand L, Lewinger JP, Lothe RA, Pike MC, Rahman N, Rubertone MV, Schwartz SM, Siegmund KD, Skinner EC, Turnbull C, Van Den Berg DJ, Wu X, Yeager M, Nathanson KL, Chanock SJ, Cortessis VK, McGlynn KA.

Hum Mol Genet. 2013 Jul 1;22(13):2748-53. doi: 10.1093/hmg/ddt109. Epub 2013 Mar 5.

39.

Can we predict who's at risk for developing bone metastases in breast cancer?

Korde LA, Gralow JR.

J Clin Oncol. 2011 Sep 20;29(27):3600-4. doi: 10.1200/JCO.2011.35.7038. Epub 2011 Aug 22. No abstract available.

PMID:
21859994
40.

Current treatment options in triple negative breast cancer.

Rodler E, Korde L, Gralow J.

Breast Dis. 2010;32(1-2):99-122. doi: 10.3233/BD-2010-0304. Review.

PMID:
21778572
41.

Pregnancy after breast cancer: if you wish, ma'am.

Pagani O, Partridge A, Korde L, Badve S, Bartlett J, Albain K, Gelber R, Goldhirsch A; Breast International Group; North American Breast Cancer Group Endocrine Working Group.

Breast Cancer Res Treat. 2011 Sep;129(2):309-17. doi: 10.1007/s10549-011-1643-7. Epub 2011 Jun 23. Review.

PMID:
21698406
42.

Variants in or near KITLG, BAK1, DMRT1, and TERT-CLPTM1L predispose to familial testicular germ cell tumour.

Kratz CP, Han SS, Rosenberg PS, Berndt SI, Burdett L, Yeager M, Korde LA, Mai PL, Pfeiffer R, Greene MH.

J Med Genet. 2011 Jul;48(7):473-6. doi: 10.1136/jmedgenet-2011-100001. Epub 2011 May 26.

43.

Are bisphosphonates ready for the adjuvant setting?

Korde LA, Gralow JR.

Oncology (Williston Park). 2010 May;24(6):480, 485. No abstract available.

44.

LINE-1 methylation is inherited in familial testicular cancer kindreds.

Mirabello L, Savage SA, Korde L, Gadalla SM, Greene MH.

BMC Med Genet. 2010 May 17;11:77. doi: 10.1186/1471-2350-11-77.

45.

No evidence of excess breast cancer risk among mutation-negative women from BRCA mutation-positive families.

Korde LA, Mueller CM, Loud JT, Struewing JP, Nichols K, Greene MH, Mai PL.

Breast Cancer Res Treat. 2011 Jan;125(1):169-73. doi: 10.1007/s10549-010-0923-y. Epub 2010 May 11.

46.

Multidisciplinary meeting on male breast cancer: summary and research recommendations.

Korde LA, Zujewski JA, Kamin L, Giordano S, Domchek S, Anderson WF, Bartlett JM, Gelmon K, Nahleh Z, Bergh J, Cutuli B, Pruneri G, McCaskill-Stevens W, Gralow J, Hortobagyi G, Cardoso F.

J Clin Oncol. 2010 Apr 20;28(12):2114-22. doi: 10.1200/JCO.2009.25.5729. Epub 2010 Mar 22.

47.

Familial testicular germ cell tumors in adults: 2010 summary of genetic risk factors and clinical phenotype.

Greene MH, Kratz CP, Mai PL, Mueller C, Peters JA, Bratslavsky G, Ling A, Choyke PM, Premkumar A, Bracci J, Watkins RJ, McMaster ML, Korde LA.

Endocr Relat Cancer. 2010 Mar 8;17(2):R109-21. doi: 10.1677/ERC-09-0254. Print 2010 Jun. Review.

48.

Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer.

Korde LA, Lusa L, McShane L, Lebowitz PF, Lukes L, Camphausen K, Parker JS, Swain SM, Hunter K, Zujewski JA.

Breast Cancer Res Treat. 2010 Feb;119(3):685-99. doi: 10.1007/s10549-009-0651-3.

49.

Soy intake is associated with increased 2-hydroxylation and decreased 16alpha-hydroxylation of estrogens in Asian-American women.

Fuhrman BJ, Pfeiffer R, Xu X, Wu AH, Korde L, Gail MH, Keefer LK, Veenstra TD, Hoover RN, Ziegler RG.

Cancer Epidemiol Biomarkers Prev. 2009 Oct;18(10):2751-60. doi: 10.1158/1055-9965.EPI-09-0388. Epub 2009 Sep 29.

50.

A mini-review of familial ovarian germ cell tumors: an additional manifestation of the familial testicular germ cell tumor syndrome.

Giambartolomei C, Mueller CM, Greene MH, Korde LA.

Cancer Epidemiol. 2009 Jul;33(1):31-6. doi: 10.1016/j.canep.2009.04.015. Epub 2009 May 30. Review.

Supplemental Content

Support Center